Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: Nested case-control study

被引:130
作者
Lehtinen, M
Dillner, J
Knekt, P
Luostarinen, T
Aromaa, A
Kimbauer, R
Koskela, P
Paavonen, J
Peto, R
Schiller, JT
Hakama, M
机构
[1] TAMPERE UNIV, TAMPERE SCH PUBL HLTH, SF-33101 TAMPERE, FINLAND
[2] NATL PUBL HLTH INST, OULU, FINLAND
[3] NATL PUBL HLTH INST, DEPT CHRON VIRAL DIS, SF-00300 HELSINKI, FINLAND
[4] KAROLINSKA INST, MICROBIOL & TUMORBIOL CTR, STOCKHOLM, SWEDEN
[5] SOCIAL INSURANCE INST, CTR RES & DEV, SF-00381 HELSINKI, FINLAND
[6] FINNISH CANC REGISTRY, SF-00170 HELSINKI, FINLAND
[7] UNIV VIENNA, SCH MED, DEPT IMMUNODERMATOL, VIENNA, AUSTRIA
[8] HELSINKI UNIV, HELSINKI, FINLAND
[9] UNIV OXFORD, CLIN TRIAL SERV UNIT, OXFORD, ENGLAND
[10] UNIV OXFORD, IMPERIAL CANC RES FUND, CANC STUDIES UNIT, OXFORD, ENGLAND
[11] NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA
来源
BMJ-BRITISH MEDICAL JOURNAL | 1996年 / 312卷 / 7030期
关键词
D O I
10.1136/bmj.312.7030.537
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-To study human papillomavirus type 16 in the aetiology of cervical c Design-Within a cohort of 18 814 Finnish women followed for up to 23 years a nested case-control study was conducted based on serological diagnosis of past infection with human papillomavirus type 16. Subjects-72 women (27 with invasive carcinoma and 45 with in situ carcinoma) and 143 matched controls were identified during the follow up. Main outcome measure- Relative risk of cervical carcinoma in presence of IgG antibodies to human papillomavirus type 16. Results-After adjustment for smoking and for antibodies to various other agents of sexually transmitted disease, such as herpes simplex virus type 2 and Chlamydia trachomatis, the only significant association was with infection with human papillomavirus type 16 (odds ratio 12.5; 95% confidence interval 2.7 to 57, 2P < 0.001). Conclusion-This prospective study provides epidemiological evidence that infection with human papillomavirus type 16 confers an excess risk for subsequent development of cervical carcinoma.
引用
收藏
页码:537 / 539
页数:3
相关论文
共 14 条
[1]  
Breslow NE, 1980, IARC SCI PUBLICATION, V32
[2]  
Chabaud Martine, 1994, P59
[3]  
DILLNER J, 1994, CANCER RES, V54, P134
[4]  
DILLNER J, 1995, INT J CANCER, V60, P377
[5]   SERUM ANTIBODIES AND SUBSEQUENT CERVICAL NEOPLASMS - A PROSPECTIVE-STUDY WITH 12 YEARS OF FOLLOW-UP [J].
HAKAMA, M ;
LEHTINEN, M ;
KNEKT, P ;
AROMAA, A ;
LEINIKKI, P ;
MIETTINEN, A ;
PAAVONEN, J ;
PETO, R ;
TEPPO, L .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1993, 137 (02) :166-170
[6]   CHLAMYDIAL ANTIGENS STABILIZED WITH FORMALIN FOR USE IN THE MICRO-IMMUNOFLUORESCENCE TEST [J].
HANNA, L ;
KESHISHYAN, H .
JOURNAL OF CLINICAL MICROBIOLOGY, 1980, 12 (03) :409-412
[7]   VIRUSES IN HUMAN CANCERS [J].
HAUSEN, HZ .
SCIENCE, 1991, 254 (5035) :1167-1173
[8]  
KIMBAUER R, 1994, JNCI-J NATL CANCER I, V86, P494
[9]   B-CELL RESPONSE IN CHLAMYDIA-TRACHOMATIS ENDOMETRITIS [J].
LEHTINEN, M ;
RANTALA, I ;
AINE, R ;
MIETTINEN, A ;
LAINE, S ;
HEINONEN, P ;
TEISALA, K ;
PUNNONEN, R ;
PAAVONEN, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1986, 5 (05) :596-598
[10]  
MARDH PA, 1989, CHLAMYDIA, P1